Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal

被引:441
作者
Tsuruo, T
Naito, M
Tomida, A
Fujita, N
Mashima, T
Sakamoto, H
Haga, N
机构
[1] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan
[2] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan
关键词
D O I
10.1111/j.1349-7006.2003.tb01345.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent progress in the development of molecular cancer therapeutics has revealed new types of antitumor drugs, such as Herceptin, Gleevec, and Iressa, as potent therapeutics for specific tumors. Our work has focused on molecular cancer therapeutics, mainly in the areas of drug resistance, apoptosis and apoptosis resistance, and survival-signaling, which is related to drug resistance. In this review, we describe our research on molecular cancer therapeutics, including molecular mechanisms and therapeutic approaches. Resistance to chemotherapeutic drugs is a principal problem in the treatment of cancer. P-Glycoprotein (P-gp), encoded by the MDR1 gene, is a multidrug transporter and has a major role in multidrug resistance (MDR). Targeting of P-gp by small-molecular compounds and/or antibodies is an effective strategy to overcome MDR in cancer, especially hematologic malignancies. Several P-gp inhibitors have been developed and are currently under clinical phased studies. In addition to the multidrug transporter proteins, cancer cells have several drug resistance mechanisms. Solid tumors are often placed under stress conditions, such as glucose starvation and hypoxia. These conditions result in topo 11 poison resistance that is due to proteasome-mediated degradation of DNA topoisomerases. Proteasome inhibitors effectively prevent this stress-induced drug resistance. Glyoxalase 1, which is often elevated in drug- and apoptosis-resistant cancers, offers another possibility for overcoming drug resistance. It plays a role in detoxification of methylglioxal, a side product of glycolysis, which is highly reactive with DNA and proteins. Inhibitors of glyoxalase I selectively kill drug-resistant tumors that express glyoxalase 1. Finally, the susceptibility of tumor cells to apoptosis induced by antitumor drugs appears to depend on the balance between pro-apoptotic and survival (anti-apoptotic) signals. PI3K-Akt is an important survival signal pathway, that has been shown to be the target of various antitumor drugs, including UCN-01 and geldanamycin, new anticancer drugs under clinical evaluation. Our present studies provide novel targets for future effective molecular cancer therapeutics.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 52 条
[11]  
HAMADA H, 1988, J BIOL CHEM, V263, P1454
[12]   SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin [J].
Horie, K ;
Tomida, A ;
Sugimoto, Y ;
Yasugi, T ;
Yoshikawa, H ;
Taketani, Y ;
Tsuruo, T .
ONCOGENE, 2002, 21 (52) :7913-7922
[13]   RESISTANCE TO ANTITUMOR AGENT-INDUCED APOPTOSIS IN A MUTANT OF HUMAN MYELOID-LEUKEMIA U937 CELLS [J].
KATAOKA, S ;
NAITO, M ;
TOMIDA, A ;
TSURUO, T .
EXPERIMENTAL CELL RESEARCH, 1994, 215 (01) :199-205
[14]   The unfolded protein response in nutrient sensing and differentiation [J].
Kaufman, RJ ;
Scheuner, D ;
Schröder, M ;
Shen, XH ;
Lee, K ;
Liu, CY ;
Arnold, SM .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (06) :411-421
[15]   Induction of apoptosis by cancer chemotherapy [J].
Kaufmann, SH ;
Earnshaw, WC .
EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) :42-49
[16]  
Kim HD, 1999, J CELL PHYSIOL, V180, P97, DOI 10.1002/(SICI)1097-4652(199907)180:1<97::AID-JCP11>3.0.CO
[17]  
2-Y
[18]  
LO TWC, 1994, J BIOL CHEM, V269, P32299
[19]  
NAITO M, 1988, J BIOL CHEM, V263, P11887
[20]  
Nakanishi K, 2002, CANCER RES, V62, P2971